author-photo

Timothy J. Guzi

Merck & Co.

78

Papers

1148

Citations

Citation Trend

Filter By

Papers (55) Sort By

Journal Conference Others

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (33)
Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B01: BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B151: BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (3)
Abstract B01: BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Crystal Structure of FGFR4 with an Irreversible Inhibitor

2015
Show All
- Source
- Cite
- Save
Citations (0)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

2015 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (179)